Literature DB >> 28474414

Clinical perineural invasion of the trigeminal and facial nerves in cutaneous head and neck squamous cell carcinoma: Outcomes and prognostic implications of multimodality and salvage treatment.

Serkan Erkan1, James M Savundra2, Bradley Wood3, Aanand N Acharya1,4, Gunesh P Rajan1,4.   

Abstract

BACKGROUND: Clinical perineural invasion (PNI) of the trigeminal and facial nerves from cutaneous head and neck squamous cell carcinoma (cutaneous HNSCC) is a rare clinical entity that poses unique therapeutic challenges.
METHODS: A retrospective chart review of a skull base oncology database was performed of patients with the diagnosis of clinical PNI from a cutaneous HNSCC. Patients who were previously untreated underwent multimodal treatment entailing surgical resection and postoperative radiotherapy (PORT) and patients who were previously treated with radiotherapy underwent salvage surgical resection between the years 2006 and 2012. Survival outcomes, such as disease-free survival (DFS) and overall survival (OS), were analyzed and correlated with surgical factors, such as margin status, previous treatment, zone involvement, and trigeminal involvement (branch-specific), as well as the pretreatment and posttreatment pain scores.
RESULTS: Of 21 patients with clinical PNI from cutaneous HNSCC, 7 patients (33%) were previously treated for their disease with primary radiotherapy. Negative tumor margins were achieved in 18 patients (86%). Three of the 7 patients (43%) undergoing salvage surgery had positive margins. One-year and 3-year DFS for previously untreated patients was 91% and 67%, respectively, whereas 1-year and 3-year DFS was 72% and 28%, respectively, for the previously treated patients. Previous radiotherapy, ophthalmic nerve involvement, and positive margins portended poorer survival outcomes in this study.
CONCLUSION: The retrospective study of this rare clinical entity demonstrates that multimodal treatment can achieve favorable survival outcomes.
© 2017 Wiley Periodicals, Inc. Head Neck 39: 1280-1286, 2017. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  cranial nerve palsy; cutaneous; head and neck; multimodal treatment; perineural invasion; squamous cell carcinoma

Mesh:

Year:  2017        PMID: 28474414     DOI: 10.1002/hed.24607

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.

Authors:  Ralf Gutzmer; Susanne Wiegand; Oliver Kölbl; Kai Wermker; Markus Heppt; Carola Berking
Journal:  Dtsch Arztebl Int       Date:  2019-09-13       Impact factor: 5.594

Review 2.  Hide-and-seek: Neurotropic squamous cell carcinoma of the periorbital region - a series of five cases and review of the literature.

Authors:  Evi M Morandi; Tina Rauchenwald; Petra Puelzl; Bernhard W Zelger; Bettina G Zelger; Benjamin Henninger; Gerhard Pierer; Dolores Wolfram
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

3.  MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.

Authors:  Aaron Chen; Alexis L Santana; Nicole Doudican; Nazanin Roudiani; Kristian Laursen; Jean-Philippe Therrien; James Lee; Diane Felsen; John A Carucci
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

4.  Facial nerve perineural spread from cutaneous squamous cell carcinoma of the head and neck: A single institution analysis of epidemiology, treatment, survival outcomes, and prognostic factors.

Authors:  Michael J C Schachtel; Mitesh Gandhi; James J Bowman; Sandro V Porceddu; Benedict J Panizza
Journal:  Head Neck       Date:  2022-02-27       Impact factor: 3.821

Review 5.  Current Surgical Therapy of Locally Advanced cSCC: From Patient Selection to Microsurgical Tissue Transplant. Review.

Authors:  Tito Brambullo; Gian Paolo Azzena; Paolo Toninello; Giuseppe Masciopinto; Alberto De Lazzari; Bernardo Biffoli; Vincenzo Vindigni; Franco Bassetto
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.